A5001838096- Glaucoma and retinal disorders
- Ocular Surface and Contact Lens
- Corneal surgery and disorders
- Intraocular Surgery and Lenses
- Facial Rejuvenation and Surgery Techniques
- Ophthalmology and Eye Disorders
- Botulinum Toxin and Related Neurological Disorders
- Retinal Diseases and Treatments
- Neurological Disorders and Treatments
- Ocular Infections and Treatments
- Corneal Surgery and Treatments
- Retinopathy of Prematurity Studies
- Retinal and Optic Conditions
- Ocular Diseases and Behçet’s Syndrome
- Pulmonary Hypertension Research and Treatments
- Allergic Rhinitis and Sensitization
- Sympathectomy and Hyperhidrosis Treatments
- Traumatic Ocular and Foreign Body Injuries
- Neonatal Respiratory Health Research
- Trauma and Emergency Care Studies
- Biochemical Acid Research Studies
- Heart Failure Treatment and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Ophthalmology and Visual Health Research
- Dermatology and Skin Diseases
Comprehensive Eye Care
2008-2023
Visual Sciences (United States)
2017
Auven Therapeutics (United States)
2016
Kala Pharmaceuticals (United States)
2016
Tufts Medical Center
2016
California Northstate University
2016
Sall Research Medical Center
2016
Wolstan & Goldberg Eye Associates
2016
Abrams Eye Institute
2016
Medical Center Ophthalmology Associates
2016
To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) timolol twice (BID).Double-masked, randomized, phase 3, noninferiority study.Patients with open-angle glaucoma or ocular hypertension (unmedicated baseline IOP >20 to <30 mm Hg at 8:00 AM) were randomized ophthalmic solution 0.02% QD (PM) 0.5% BID. The primary endpoint was mean AM, 10:00 4:00 PM week 2, 6, month 3 in patients <25 (per-protocol population). Safety recorded over 6-month...
To assess the efficacy and safety of difluprednate ophthalmic emulsion 0.05% (Durezol) 2 or 4 times a day compared with those placebo in treatment inflammation pain associated ocular surgery.Twenty-six clinics United States.One after unilateral surgery, patients who had an anterior chamber cell grade higher (>10 cells) were treated 1 drop (vehicle) study eye for 14 days. This was followed by 14-day tapering period 7-day evaluation. Outcome measures included cleared (grade 0, <or=1 cell),...
Abstract Objectives This study evaluated the safety of topical lipoic acid choline ester (UNR844, 1.5%) ophthalmic solution and its efficacy in improving distance-corrected near visual acuity (DCNVA) subjects with presbyopia. Subjects methods was a prospective, randomized, double-masked, multicentre clinical trial. diagnosis presbyopia ( n = 75) were randomized 2:1 to UNR844 or placebo. On days 1–7, all dosed unilaterally (twice day, b.i.d.) their non-dominant eye ensure tolerability prior...
Purpose: The safety of KPI-121 0.25%, an ophthalmic nanoparticle suspension loteprednol etabonate, was evaluated in subjects with dry eye disease (DED) one phase 2 and three 3 randomized trials similar design. Methods: Adults DED received 0.25% or vehicle drops 4 times daily (QID) for ≥2 weeks; 1430 1438 drops. Main assessments were adverse events (AEs) intraocular pressure (IOP). As a common side effect associated the use ocular corticosteroids is elevated IOP, history current diagnosis...
Purpose: The aim of this study was to assess the long-term safety and efficacy perfluorohexyloctane (PFHO) ophthalmic drop (formerly NOV03) for treatment dry eye disease (DED). Methods: KALAHARI a phase 3, multicenter, single-arm, open-label extension in patients aged 18 years or older with DED associated Meibomian gland dysfunction who completed randomized, double-masked, hypotonic saline-controlled GOBI study. Patients instilled 1 PFHO (MIEBO, Bausch + Lomb) 4 times daily both eyes 52...
Treatment of acquired blepharoptosis (ptosis) is currently limited to surgical intervention.To examine the efficacy and safety oxymetazoline hydrochloride, 0.1%, ophthalmic solution (oxymetazoline, 0.1%) in participants with ptosis.This pooled analysis 2 randomized, double-masked, placebo-controlled, multicenter phase 3 clinical trials included 9 years older ptosis superior visual field deficit. The studies were conducted across 16 27 sites United States. Patients enrolled from May 2015...
Isunakinra, formerly known as EBI-005, is a novel interleukin (IL)-1 receptor inhibitor developed for topical treatment of patients with dry eye disease (DED). This phase 1b/2a multicenter, double-masked, randomized, vehicle controlled environmental trial assessed the safety and biological activity isunakinra in moderate to severe DED.Subjects (N=74) were randomized (placebo) or (5 20 mg/mL) 3×/daily 6 weeks. Evaluations included safety, tolerability, signs (corneal fluorescein staining...
Oxymetazoline 0.1% is a novel ophthalmic agent for the treatment of acquired blepharoptosis in adults that has been shown to improve upper eyelid elevation and superior visual field deficits. This analysis characterized rapid onset with once-daily oxymetazoline durability this effect over 42 days.Pooling data from two prospective, randomized, placebo-controlled, phase 3 studies, change marginal reflex distance 1 (MRD-1) was evaluated at range post-instillation time points on days 1, 14, 42....
The authors have previously validated an Ocular Pressure Estimator (OPE) that can estimate the intraocular pressure (IOP) during external ocular compression (EOC). now apply OPE in clinical states where EOC is clinically important. original work described for two periods of risk: sleep and digital massage (DOM) maneuver used by surgeons after trabeculectomy to keep operation functional. Other risk are then reviewed.
An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study's objective to evaluate the safety profile when administered once daily 14-84 days.Pooled analysis examined outcomes from four randomized, double-masked, placebo-controlled clinical trials conducted at 6, 16, 27, and 35 sites, respectively, United States. In total, 568 participants with were evaluated. Median age 66 years 74.8% female. Overall, 375 self-administered...
Ophthalmic surgery has evolved substantially during the last 40 years to include minimally invasive procedures and premium intraocular lens implantation. Patients physicians who invest in such advanced technology, materials expect equally postoperative treatments. pharmacology, however, seen only modest gains this same period. Difluprednate ophthalmic emulsion, a novel difluorinated prednisolone derivative, is first strong steroid be developed past 35 shown reduce pain effectively, an...
Purpose: To describe a noninvasive instrument that estimates intraocular pressure during episodes of external globe compression and to demonstrate the accuracy reliability this device by comparing it pressures simultaneously manometrically measured in cannulated eyes. Methods: A thin fluid-filled bladder was constructed from flexible inelastic plastic sheeting connected transducer with high tubing. The output sent an amplifier recorded. This validated measuring induced while digital applied...
To evaluate the safety and efficacy of a preservative-free latanoprost 0.005% formulation (T2345) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) compared to benzalkonium chloride-preserved (BPL) United States (US).A prospective, randomized, multicenter, observer-masked, parallel-group study enrolled 335 diagnosed POAG OHT from 31 US sites who had adequately controlled intraocular pressure (IOP; ≤18 mm Hg) monotherapy. After ≥72-hour washout period, were...